Premature Ejaculation and Its Pharmacological Treatment

Introduction and objective Ejaculatory dysfunction, erectile dysfunction (ED), and decreased libido are the major components of male sexual dysfunction. Premature Ejaculation (PE) however, is actually more prevalent, involving up to 31 %of men aged 18-59 years (1). PE is more prevalent in young men and in men who lack sexual experience and frequency. Our objectives were to assess new avenues in the PE and its Pharmacological Treatment. Material and Methods A MedLine search was performed for per-reviewed articles on Pharmacological Treatment in managing of Premature Ejaculation. Results Eight manuscripts that examined pharmacological treatment were retrieved. Three studies used drugs as monotherapy and two used it in combination with serotonin selective reuptake inhibitor (SSRI). Two preclinical and early clinical studies with oxytocin antagonists are in progress, but results are still to be released. One may also postulate that dopaminergic drugs interacting with selected receptor subtypes may have potential in this indication. Conclusion Encouraging evidence supports the role of phosphodiesterase type 5 inhibitors (PDE 5 Is) in the treatment of PE. SSRIs are one the main categories of pharmacological agents that have been evaluated for PE therapy. Furthermore, in delaying ejaculation, there are a variety of other central neurotransmitters that could be targeted. My feeling is that pharmacological research is still in its infancy in this domain.